Skip to main content

Seize the digital momentum

Measuring the return from pharmaceutical innovation 2022

Our series of annual reports on Measuring the return from pharmaceutical innovation has provided insights into the state of biopharma R&D since 2010. We have expanded the analysis over time and our data set now covers the top 20 pharma companies by R&D spend. This year’s analysis demonstrates the step change we anticipated, in our 2021 report Nurturing growth, is yet to be realised.

Our latest report looks at the current state of R&D returns for 20 leading biopharma companies as well as their pipeline composition and sources of innovation. What is clear is that revitalising today's clinical trials for a healthier tomorrow entails thoughtful digitalisation of clinical trial processes to create a seamless experience for patients and staff which could drastically improve trial efficiency, enhance scientific rigor, and expand health equity.

Did you find this useful?

Thanks for your feedback

If you would like to help improve further, please complete a 3-minute survey